

Guidance Document on the Management of Inadvertent Vaccine Errors

June 3, 2021

Overview

This document is intended to assist healthcare providers by providing an approach to managing COVID-19 vaccines that are administered in a manner that differs from the recommendations of the manufacturer and/or the National Advisory Committee on Immunization (NACI) (referred to as vaccine administration errors). This document builds on guidance developed by [CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States](#) and the guidance developed by Public Health Ontario, with input from the Canadian Immunization Committee and the National Advisory Committee on Immunization.

There is limited evidence to guide the management of these situations. This document provides guidance only. Health authority protocols may differ from this guidance document and clinical judgement in particular situations may also result in different management decisions than outlined below.

Note that this document is to be used only to manage errors that have already occurred. The product monograph and recommendations from the National Advisory Committee on Immunization should be followed when administering COVID-19 vaccines.

Steps to be taken after an error is recognized

Following the identification of an inadvertent vaccine administration error, healthcare providers should:

- Inform the recipient of the vaccine administration error as soon as possible after it is identified. The recipient should be informed of any implications/recommendations for future doses, and possibility for local or systemic reactions and impact on the effectiveness of the vaccine (if applicable and as known).
- Report all errors or near miss incidents in accordance with the institutional medication error or professional body's reporting process, including the BC Patient Safety Learning System (PSLS).
- If an inadvertent vaccine administration error results in an adverse event following immunization (AEFI), complete the [AEFI Case Report Form](#) and submit it to the local public health authority. Information on AEFI reporting can be found in the [BC Immunization Manual, Part 5: Adverse events Following Immunization](#).
- Determine how the vaccine administration error occurred and implement strategies to prevent it from happening again.
- Serologic testing to assess vaccine-induced immunity following COVID-19 vaccine errors to guide management decisions is generally not recommended. Providers are encouraged to contact their local public health authority for advice if considering using serology to investigate an error.
- Additional resources on vaccine administration practices can be found in the BC Immunization Manual, [Appendix B: Administration of Biological Products](#).

Type	Administration error	Interim guidance on how to consider the dose and recommended action
Site/route	Incorrect site (i.e., site other than the deltoid muscle [preferred site] or anterolateral thigh [alternate site])	<p>Consider this a valid dose.</p> <p>Inform the recipient of the error and the potential for local and systemic adverse events and that the dose is considered acceptable.</p>
	Incorrect route (e.g., subcutaneous)	<p>Consider this a valid dose.</p> <p>Inform the recipient of the error and potential for local and systemic adverse events and that the dose is considered acceptable.</p>
Age	Use at a younger age than authorized by Health Canada and/or recommended by NACI	<p>Pfizer-BioNTech vaccine:</p> <p>Consider this a valid dose.</p> <p>Give the second dose at the recommended interval if the client is at least 12 years of age or when authorized for the client’s age (if authorization is extended to below 12 years of age).</p> <p>Moderna vaccine:</p> <p>Consider this a valid dose.</p> <p>Give the second dose of an mRNA vaccine authorized for the client’s age at the recommended interval. Note: Health Canada approval for 12-17 year olds is expected in mid-June.</p> <p>AstraZeneca/COVISHIELD vaccines:</p> <p>Consider this a valid dose.</p> <p>Give the second dose as an mRNA vaccine authorized for the client’s age at the recommended interval.</p>

Type	Administration error	Interim guidance on how to consider the dose and recommended action
		<p>Janssen vaccine:</p> <p>Consider this a valid dose.</p> <p>The vaccine series is considered complete.</p>
Intervals	Two doses of a COVID-19 given too close together in time (including on the same day)	<p>Inform the recipient of the potential for local and systemic adverse events.</p> <p>If the second dose was administered 18 or more days after the first for Pfizer-BioNTech or 21 or more days after the first for Moderna or 4 or more weeks after the first for AstraZeneca, consider both doses valid, and the series complete.</p> <p>If the second dose was administered less than 18 days after the first for Pfizer-BioNTech or less than 21 days after the first for Moderna or less than 4 weeks after the first dose of AstraZeneca, consider the second dose invalid and repeat at the recommended interval between first and second dose for your jurisdiction (counting from the date of the invalid dose). If a significant local or systemic reaction from the invalid dose occurs, consult an allergist/immunologist before repeating. When repeating the dose, inform the recipient of the potential for local and systemic adverse events.</p>
	Second dose administered later than the recommended interval	If administration of the second dose of a COVID-19 vaccine is delayed beyond the recommended interval, the second dose should be provided as soon as possible. No further doses are required.
Dosage	Higher-than-authorized dose volume administered	Consider this dose valid.

Type	Administration error	Interim guidance on how to consider the dose and recommended action
(see Diluent section below for specific information regarding Pfizer-BioNTech and the diluent)		Inform the recipient of the potential for local and systemic adverse events. ¹
	Lower-than-authorized dose volume administered (e.g. leaked out, equipment failure, recipient pulled away)	If less than a full dose is administered, consider it invalid. Administer a full repeat dose immediately in the opposite arm. Inform the recipient of the potential for local and systemic adverse events. ¹
	More or less than the authorized number of doses obtained from the vial	As long as the correct dosage were drawn up per dose (and the correct amount of diluent was used, if applicable) the doses are considered valid.
Storage and Handling	Dose administered after improper storage and handling (e.g., temperature excursion)	Contact BCCDC Pharmacy for guidance. If BCCDC provides information suggesting the dose should be considered invalid and if that seems appropriate based on clinical judgement, a repeated dose may be given as soon as possible in the opposite arm. Inform the recipient of the potential for local and systemic adverse events. ¹
	Dose administered past the expiration/beyond use date	Contact BCCDC Pharmacy for guidance. If BCCDC provides information suggesting that the dose should be considered invalid and if that seems appropriate based on clinical judgement, a repeated dose may be given as soon as possible in the opposite arm. Inform the recipient of the potential for local and systemic adverse events. ¹
Diluent (Pfizer-BioNTech only)	Incorrect diluent type (e.g., sterile water, bacteriostatic 0.9% NS)	Contact BCCDC Pharmacy for guidance. If BCCDC provides information suggesting that the dose be considered invalid and if that seems appropriate based on clinical judgement, a repeated dose may be given as soon as possible in the opposite arm. Inform

Type	Administration error	Interim guidance on how to consider the dose and recommended action
		the recipient of the potential for local and systemic adverse events. ¹
	ONLY diluent administered (i.e., sterile 0.9% sodium chloride)	Inform the recipient that no vaccine was administered. Administer the authorized (appropriately diluted) dose as soon as possible in the opposite arm.
	Too much diluent administered (more than 2.0 mL of diluent) (based on 0.3 mL dose administered)	If more than 2.0 mL of diluent was added to the vial, consider this an invalid dose. Administer a full repeat dose immediately in the opposite arm. Inform the recipient of the potential for local and systemic adverse events. ¹
	No diluent or less than the recommended diluent, resulting in higher than the authorized dose (based on 0.3 mL dose administered)	Consider this dose valid. Inform the recipient of the potential for local and systemic adverse events. ¹

¹ If the client requires a final dose to complete the series, an interval of 8 weeks should be used as outlined on the [government of B.C. website](#). The client should be advised regarding the potential for local and systemic adverse events following the final dose. If the client who requires a final dose has developed a significant local or systemic reaction from an earlier dose, the decision to administer the final dose should be assessed on a case-by-case basis by the Medical Health Officer and/or in consultation with an allergist/immunologist.

References

Centres for Disease Control and Prevention (CDC). Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Available from: <https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>

National Advisory Committee on Immunization (NACI). Recommendations on the use of COVID-19 vaccines. Available from: <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html>

Public Health England. COVID-19 vaccination programme Information for healthcare practitioners Republished 20 May 2021 Version 3.7. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/988091/COVID-19_vaccination_programme_guidance_for_healthcare_workers_20_May_2021_v3.7.pdf